Siemens Healthineers AG
5-year stock timeline
Siemens Healthineers (SHL.XETRA) underwent significant strategic change between 2020 and 2026, anchored by the Varian acquisition, a pronounced COVID-testing revenue cycle, and the subsequent integration phase. The stock closed at 36.3 on April 1, 2026.
Key milestones
In August 2020, Siemens Healthineers announced an all-cash acquisition of Varian for approximately USD 16.4 billion. The deal closed in April 2021, establishing Varian as a dedicated business segment with a target of at least EUR 300 million in annual EBIT synergies by fiscal 2025.
Late 2021 through 2022 saw rapid-antigen COVID-19 testing revenues spike sharply, lifting Diagnostics results and forward guidance. This normalized through 2022, creating uneven quarterly comparisons as testing revenue declined and rolled off the base.
How the market saw it
The company's inclusion in the DAX coincided with pandemic-era momentum, reframing Siemens Healthineers in investors' minds from a pure imaging vendor toward a broader healthcare leader. Post-Varian, the dominant theme became transformation into an integrated cancer-care platform, though integration execution and synergy delivery remained in focus.
As COVID testing normalized, attention shifted to sustainable organic growth, margin realization, and earnings quality. Management guidance and occasional beats shaped sentiment through 2023 and 2024.
Price action
From 2020 into early 2021, the stock advanced sharply on Varian announcement and COVID tailwinds. Through 2022, volatility increased and prices pulled back as testing comparisons dissolved and macro headwinds—notably China lockdown effects on equipment demand—weighed on near-term sales.
From 2023 through 2026, the stock stabilized into a multi-year consolidation range, punctuated by rallies on earnings beats and guidance updates. The market appeared to be pricing in Varian integration progress, synergy realization, and longer-term growth potential.
Key risks and downside factors
Siemens Healthineers operates in diagnostic imaging, laboratory diagnostics, and oncology alongside established competitors like Philips, Roche, Abbott, and Danaher. The company straddles two business models—capital equipment (imaging systems, Varian radiotherapy) paired with recurring consumables and services—which broadens its market reach but ties performance to hospital spending cycles and competitive pricing dynamics. The business faces headwinds from regulatory and reimbursement shifts, supply constraints, currency and interest-rate swings, and intensifying competition in digital and AI capabilities from both incumbents and newer entrants.
- Intense competition from large diversified med-tech firms like Philips, Abbott, and Danaher creates meaningful pressure on both pricing and market share.
- Regulatory shifts and reimbursement pressures in diagnostics and radiotherapy could weigh on demand and slow approval timelines.
- Hospital capital spending follows predictable cycles, and when the broader economy weakens, equipment orders for imaging systems and Varian radiotherapy gear tend to drop sharply.
- Supply-chain disruptions, component shortages, and currency fluctuations tend to squeeze margins through higher costs.
Competitive landscape
Siemens Healthineers competes in a landscape dominated by GE HealthCare, Philips, Roche, Danaher, Thermo Fisher, and Abbott. The competitive advantage belongs to those with scale, established service networks, breadth across lab and imaging systems, and the ability to move quickly in molecular and point-of-care diagnostics. The company faces headwinds from regulatory shifts and reimbursement pressure, pricing competition, supply constraints that periodically tighten, and the inherent lumpiness of capital equipment spending in healthcare systems.
| Company | Ticker |
|---|---|
| GE HealthCare Technologies | GEHC.NASDAQ |
| Danaher Corporation | DHR.NYSE |
| Thermo Fisher Scientific Inc. | TMO.NYSE |
| Abbott Laboratories | ABT.NYSE |
Private competitors
- Canon Medical Systems
- Lunit
Get More Stock Analyses Like This
Receive hand-picked stock recommendations with detailed analyses every week
Start Free TrialPerformance Figures of Siemens Healthineers AG
Relative Performance vs Benchmarks
| Period | Siemens Healthineers AG | vs DAX | vs S&P 500 (SPY) |
|---|---|---|---|
| 1M | -12.26% | -6.29% | -7.27% |
| 3M | -17.25% | -11.85% | -12.88% |
| 6M | -21.97% | -17.00% | -19.70% |
| 1Y | -25.83% | -28.61% | -43.09% |
| 3Y | -27.36% | -75.59% | -92.44% |
| 5Y | -13.99% | -67.34% | -87.81% |
Get More Stock Analyses Like This
Receive hand-picked stock recommendations with detailed analyses every week
Start Free TrialHistorical valuation trends
How the company’s key valuation ratios (P/E, P/S, P/B and P/CF) have evolved over time compared to today.
| Period | P/E Ratio | P/S Ratio | P/B Ratio | P/CF Ratio |
|---|---|---|---|---|
| Current | 19.2 | 1.7 | 2.2 | 15.6 |
| 1Y ago | 26.8 | 2.4 | 3.0 | 17.9 |
| 3Y ago | 39.0 | 2.7 | 3.4 | 30.0 |
| 5Y ago | 31.7 | 3.3 | 3.4 | 19.6 |
Key Metrics
Valuation Metrics
Profitability Metrics
Growth Metrics
Dividend history
Long-term record of paid dividends (amount per share and dividend yield at the time of payment).
| Year | Dividend | Yield at payment | Avg. yield |
|---|---|---|---|
| 2026 | 1.00 EUR | 2.35% | 1.85% |
| 2025 | 0.95 EUR | 1.66% | |
| 2024 | 0.95 EUR | 1.86% | |
| 2023 | 0.95 EUR | 1.85% | |
| 2022 | 0.85 EUR | 1.52% | |
| 2021 | 0.80 EUR | 1.64% | |
| 2020 | 0.80 EUR | 1.94% | |
| 2019 | 0.70 EUR | 1.98% |
Earnings history & estimates
Historical earnings performance shows how consistently the company meets or exceeds analyst expectations. Forward estimates provide insight into expected profitability and growth trajectory.
Historical earnings performance
Upcoming earnings report
Analyst estimates for upcoming periods
Key financial figures
Selected income statement, balance sheet and cash flow figures. Annual and quarterly, based on reported IFRS/GAAP financials.
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | 23.38B | 22.36B | 21.68B | 21.71B | 18.00B |
| Operating income (EBIT) | 3.44B | 3.30B | 2.44B | 3.06B | 2.78B |
| Net income | 2.14B | 1.94B | 1.51B | 2.04B | 1.73B |
| Free cash flow | 2.27B | 1.77B | 1.28B | 1.65B | 2.26B |
| Total assets | 44.37B | 46.05B | 46.68B | 49.06B | 41.93B |
| Equity | 18.04B | 18.20B | 18.08B | 19.84B | 16.04B |
| Net debt | 12.89B | 13.53B | -1.01B | -704.00M | 12.99B |
PWP Leeway UG (haftungsbeschränkt)
